PRESENTATION
Q3 2024 — Results presentation (earnings call)
Q3 2024PDF · 23 pages3.8 MB
-- 1 of 23 -- -- 2 of 23 -- -- 3 of 23 -- -- 4 of 23 -- -- 5 of 23 -- -- 6 of 23 -- -- 7 of 23 -- -- 8 of 23 -- -- 9 of 23 -- ■ ■ • • • • • • • • • • • • • • • • -- 10 of 23 -- • • • • • • • • • • • • • • • ■ ■ -- 11 of 23 -- -- 12 of 23 -- -- 13 of 23 -- -- 14 of 23 -- -- 15 of 23 -- -- 16 of 23 -- -- 17 of 23 -- -- 18 of 23 -- -- 19 of 23 -- • • • • • • • • • • • -- 20 of 23 -- -- 21 of 23 -- -- 22 of 23 -- = Achieved POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA Sum of Check Change Sum of Check Change Sum of Check Change Phase III OPSUMIT (macitentan) P US OPSUMIT (macitentan) US SIMPONI (golimumab) P TREMFYA (guselkumab) P EU Pediatric Pulmonary Arterial Hypertension (TOMORROW) Pediatric Pulmonary Arterial Hypertension (TOMORROW) EU Pediatric Ulcerative Colitis Crohn's Disease (GALAXI) P US OPSYNVI (macitentan/tadalafil STCT) UPTRAVI (selexipag) STELARA (ustekinumab) P TREMFYA (guselkumab) P EU Pulmonary Arterial Hypertension P EU Pediatric Pulmonary Arterial Hypertension (SALTO) P EU Pediatric Crohn's Disease Ulcerative Colitis (QUASAR) P US EDURANT (rilpivirine) REKAMBYS US TREMFYA (guselkumab) P RYBREVANT (amivantamab) P EU HIV pediatric 2-12 year old P EU HIV Adolescents Pediatric Psoriasis Subcutaneous (PALOMA-3) P US^ BALVERSA (erdafitinib) P US nipocalimab P US TREMFYA (guselkumab) P seltorexant P EU Urothelial Cancer (THOR) P EU Generalized Myasthenia Gravis P EU Crohn's Disease (GALAXI) Adjunctive treatment for major depressive disorder with insomnia symptoms P US DARZALEX (daratumumab) P US SPRAVATO (esketamine) monotherapy US TREMFYA (guselkumab) P nipocalimab EU Frontline multiple myeloma transplant eligible (PERSEUS) Treatment Resistant Depression (TRD4005) Pediatric Juvenile Psoriatic Arthritis Generalized Myasthenia Gravis P US CARVYKTI (ciltacabtagene autoleucel) P US RYBREVANT (amivantamab) P US TREMFYA (guselkumab) P TREMFYA (guselkumab) P EU Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4) P EU Subcutaneous (PALOMA-3) P EU Ulcerative Colitis (QUASAR) Crohn's Disease Subcutaneous Induction (GRAVITI) P US RYBREVANT (amivantamab) P US DARZALEX (daratumumab) US TREMFYA (guselkumab) P SPRAVATO (esketamine) P EU Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON) P EU Frontline multiple myeloma transplant eligible (PERSEUS) Ulcerative Colitis Subcutaneous Induction (ASTRO) Treatment Resistant Depression monotherapy (TRD4005) P US RYBREVANT P US DARZALEX (daratumumab) P US TREMFYA (guselkumab) DARZALEX (daratumumab) P EU Non Small Cell Lung Cancer 2L (MARIPOSA-2) P EU Frontline multiple myeloma transplant ineligible (CEPHEUS) P EU Crohn's Disease Subcutaneous Induction (GRAVITI) Amyloidosis (ANDROMEDA) P US RYBREVANT / LAZCLUZE US DARZALEX (daratumumab) Phase II EU Non Small Cell Lung Cancer (MARIPOSA) EU Smoldering Multiple Myeloma (AQUILA) P nipocalimab Sjogren's Disease (DAHLIAS) P US TREMFYA (guselkumab) Ulcerative Colitis (QUASAR) P TAR-200 (RIS/gemcitabine plus cetrelimab) Non Muscle Invasive Bladder Cancer (SunRISe-1) Johnson & Johnson Innovative Medicine Pipeline Key Events in 2024* *This information is as of October 15, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. ^ BALVERSA US Full Approval -- 23 of 23 --